Drug Type CAR-T |
Synonyms aLAG3-IL-2c(Anwita Biosciences), AWT 026, AWT026 |
Target |
Action modulators, inhibitors |
Mechanism IL-2 modulators(Interleukin-2 modulators), LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Preclinical | United States | 01 Nov 2024 |





